Eva Pros

1.1k total citations
19 papers, 619 citations indexed

About

Eva Pros is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Eva Pros has authored 19 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Neurology. Recurrent topics in Eva Pros's work include Neurofibromatosis and Schwannoma Cases (6 papers), Sarcoma Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Eva Pros is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (6 papers), Sarcoma Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Eva Pros collaborates with scholars based in Spain, France and Netherlands. Eva Pros's co-authors include Montse Sánchez‐Céspedes, Conxi Lázaro, Eduard Serra, Octavio A. Romero, Pere Fábregas, Maria Saigí, Carolina de la Torre, Antonio Gómez, Sebastián Morán and Manuel Torres-Diz and has published in prestigious journals such as Nature Communications, Cancer Research and Clinical Cancer Research.

In The Last Decade

Eva Pros

19 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Pros Spain 14 372 160 159 133 116 19 619
Suzanne E. Little United Kingdom 14 538 1.4× 164 1.0× 138 0.9× 153 1.2× 56 0.5× 15 847
Elena Lualdi Italy 7 355 1.0× 147 0.9× 141 0.9× 48 0.4× 147 1.3× 9 568
Domenico Trombetta Italy 12 358 1.0× 209 1.3× 266 1.7× 54 0.4× 83 0.7× 36 731
Ken Kikuchi Japan 16 472 1.3× 289 1.8× 244 1.5× 95 0.7× 87 0.8× 36 736
Tamara Utermark United States 12 404 1.1× 82 0.5× 170 1.1× 160 1.2× 48 0.4× 14 626
Kristina Ruuth Sweden 13 392 1.1× 88 0.6× 223 1.4× 387 2.9× 93 0.8× 23 694
David Eaves United States 8 191 0.5× 166 1.0× 94 0.6× 307 2.3× 53 0.5× 9 539
Curt J. Essenburg United States 9 180 0.5× 106 0.7× 149 0.9× 61 0.5× 54 0.5× 17 413
Frank Mendrzyk Germany 9 660 1.8× 98 0.6× 200 1.3× 120 0.9× 63 0.5× 10 952
Bandana Sharma United States 8 662 1.8× 128 0.8× 283 1.8× 107 0.8× 51 0.4× 16 833

Countries citing papers authored by Eva Pros

Since Specialization
Citations

This map shows the geographic impact of Eva Pros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Pros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Pros more than expected).

Fields of papers citing papers by Eva Pros

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Pros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Pros. The network helps show where Eva Pros may publish in the future.

Co-authorship network of co-authors of Eva Pros

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Pros. A scholar is included among the top collaborators of Eva Pros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Pros. Eva Pros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Saigí, Maria, José Luís Mate, Enric Carcereny, et al.. (2024). HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 189. 107502–107502. 2 indexed citations
2.
Alburquerque-Béjar, Juan J., Maria Saigí, Antonio Gómez, et al.. (2023). MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. Cell Reports Medicine. 4(4). 101006–101006. 19 indexed citations
3.
Saigí, Maria, Enric Carcereny, Teresa Morán, et al.. (2022). Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer. Cancer Treatment Reviews. 109. 102430–102430. 6 indexed citations
4.
Romero, Octavio A., Juan J. Alburquerque-Béjar, Antonio Gómez, et al.. (2021). SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature Communications. 12(1). 4319–4319. 36 indexed citations
5.
Saigí, Maria, Juan J. Alburquerque-Béjar, Carolina Pereira, et al.. (2018). MET -Oncogenic and JAK2 -Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer. Clinical Cancer Research. 24(18). 4579–4587. 75 indexed citations
6.
Giménez‐Xavier, Pol, Eva Pros, Sebastián Morán, et al.. (2018). Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells. Oncotarget. 9(59). 31549–31558. 7 indexed citations
7.
Giménez‐Xavier, Pol, Eva Pros, Sebastián Morán, et al.. (2017). Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells. Molecular Cancer Therapeutics. 16(7). 1366–1376. 24 indexed citations
8.
Saigí, Maria, Anne McLeer‐Florin, Eva Pros, et al.. (2017). Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer. Clinical & Translational Oncology. 20(7). 881–888. 15 indexed citations
9.
Torres-Diz, Manuel, Eva Pros, Antonio Gómez, et al.. (2014). Abstract 2477: Max inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Research. 74(19_Supplement). 2477–2477. 1 indexed citations
10.
Romero, Octavio A., Manuel Torres-Diz, Eva Pros, et al.. (2013). MAX Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1. Cancer Discovery. 4(3). 292–303. 126 indexed citations
11.
Pros, Eva, Sylvie Lantuéjoul, Lydia Sánchez-Verde, et al.. (2013). Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. International Journal of Cancer. 133(4). 898–907. 22 indexed citations
12.
Menéndez, Mireia, Joan Castellsagué, Eva Pros, et al.. (2011). Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment. 132(3). 979–992. 13 indexed citations
13.
Fernández‐Rodríguez, Juana, Ernest Terribas, Eva Pros, et al.. (2010). Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH. Human Mutation. 32(1). 78–90. 53 indexed citations
14.
Rodrı́guez-Nieto, Salvador, Eva Pros, Juan Torres‐Lanzas, et al.. (2010). Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Human Mutation. 32(2). E1999–E2017. 66 indexed citations
15.
Pros, Eva, Juana Fernández‐Rodríguez, Llúcia Benito‐Aracil, et al.. (2009). Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment. European Journal of Human Genetics. 18(5). 614–617. 15 indexed citations
16.
Pros, Eva, Juana Fernández‐Rodríguez, Llúcia Benito‐Aracil, et al.. (2009). Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Human Mutation. 30(3). 454–462. 41 indexed citations
17.
Pros, Eva, et al.. (2008). Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Human Mutation. 29(9). E173–E193. 78 indexed citations
18.
Serra, Eduard, Eva Pros, Eva López, et al.. (2007). Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients. Genes Chromosomes and Cancer. 46(9). 820–827. 4 indexed citations
19.
Pros, Eva, Sara Larriba, Eva López, et al.. (2006). NF1mutation rather than individual genetic variability is the main determinant of theNF1-transcriptional profile of mutations affecting splicing. Human Mutation. 27(11). 1104–1114. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzanne E. Little Breakdown of academic impact, for papers by Elena Lualdi Breakdown of academic impact, for papers by Domenico Trombetta Breakdown of academic impact, for papers by Ken Kikuchi Breakdown of academic impact, for papers by Tamara Utermark Breakdown of academic impact, for papers by Kristina Ruuth Breakdown of academic impact, for papers by David Eaves Breakdown of academic impact, for papers by Curt J. Essenburg Breakdown of academic impact, for papers by Frank Mendrzyk Breakdown of academic impact, for papers by Bandana Sharma
Rankless by CCL
2026